JPRN-jRCT2071220057已完成1 期
A phase I open-label study to investigate the absorption, metabolism and excretion of [14C]KDT-3594 following single oral administration in healthy adult male subjects
Shimizu Yoshitaka0 个研究点目标入组 8 人开始时间: 2022年10月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •Healthy Japanese male
- •- Age: >18 to =<45 years old
- •- BMI: >=18.5 to <25.0 kg/m2
- •- Body weight: >=50 kg
排除标准
- •Subjects with complication or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, (including alcoholic liver disease, non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary liver disease), psychiatric, neurological, or allergic disease (including drug allergy, but excluding untreated, asymptomatic or seasonal allergy at the time of administration)
研究者
相似试验
已完成
不适用
A phase I, open label study to investigate the absorption, metabolism and excretion of 14C-ESN-364 in healthy menopausal female volunteers.NL-OMON46563Ogeda6
已完成
不适用
A phase 1, open-label study to characterize the absorption, metabolism and excretion of 14C-JNJ-63623872 after a single dose in healthy male subjectsInfluenza ARNA-virus10047438NL-OMON42724Janssen-Cilag6
已完成
不适用
A phase 1, open-label study to characterize the absorption, metabolism, and excretion of 14C-JNJ-53718678 after a single oral dose in healthy adult male subjectsRSV10047438NL-OMON43122Janssen Sciences Ireland UC6
已完成
不适用
A phase 1, open-label study to investigate the absorption, metabolism, excretion, and mass balance of [14C]pacritinib following a single oral dose in healthy male subjects.Chronic Myeloproliferative Disordersabnormal growth of blood cells in the bone marrowMyeloproliferative disordersNL-OMON41159CTI BioPharma Corporation6
已完成
不适用
A phase I, open-label study to investigate the absorption, metabolism, excretion, and mass balance of [14C]QLT091001 following single oral dose in healthy male subjectsNL-OMON35776QLT Inc.6